Trial Profile
To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers in Chinese Adult Male Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2018
Price :
$35
*
At a glance
- Drugs Surufatinib (Primary)
- Indications Biliary cancer; Neuroendocrine tumours; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma
- 12 Jun 2018 Status changed from not yet recruiting to completed.
- 02 Apr 2018 New trial record